U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07677306) titled 'Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT' on June 24.
Brief Summary: This study plan aims to enroll adult patients diagnosed with myelodysplastic syndrome (MDS) who are scheduled to receive T-cell-replete haploidentical hematopoietic stem cell transplantation. After obtaining written informed consent, participants will receive either reduced-toxicity Bu/Flu/Cy/ATG conditioning regimen (for patients aged >=55 years) or standard myeloablative modified Bu/Cy+ATG conditioning regimen (for patients aged <55 years) followed by unified post-transplant immunosuppression and supportive care. The objective is to prospect...